Results 141 to 150 of about 21,216 (279)

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj  

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Frontiers in Microbiology, 2019
More than 10 million people worldwide are infected with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to severe adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy ...
Michał S. Barski, Jordan J. Minnell, Goedele N. Maertens   +2 more
doaj   +1 more source

Physiologically Based Pharmacokinetic Modelling of UGT Substrate Drugs Lamotrigine and Raltegravir during Pregnancy

Future Pharmacology
Pregnancy is associated with various physiological changes that can significantly impact the disposition of drugs. To further the insight into how pregnancy affects the pharmacokinetics of drugs at different stages, clinical studies can be simulated ...
Monika Berezowska, Paola Coppola, Venkatesh Pilla Reddy, Pradeep Sharma   +3 more
doaj   +1 more source

Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs

Качественная клиническая практика, 2018
Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background ...
Y. I. Ashikhmin, D. Yu. Belousov
doaj  

1575A 28-day high-dose safety and pharmacokinetics study of raltegravir in healthy subjects [PDF]

, 2014
Rajesh Krishna, Matthew L. Rizk, Valerie Schulz, Jolanda Bruggencate-Broeders, Ran Liu, Patrick Larson, Khalid Abou-Farha   +6 more
openalex   +1 more source

Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV

, 2020
Stefan Adrian, Hongyu Miao, Han Feng, Ann Scherzinger, Giulia Nardini, Barbara Beghetto, Enrica Roncaglia, Guido Ligabue, Jovana Milić, Giovanni Guaraldi, Jordan E. Lake, Kristine M. Erlandson   +11 more
openalex   +2 more sources

Raltegravir 800 mg once‐daily is efficacious in already virologically suppressed patients [PDF]

, 2012
Derek Ward, Robert Grant
openalex   +1 more source

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach

Journal of Infection and Public Health, 2020
Purushothaman Indu, M. Rameshkumar, N. Arunagirinathan, N. Al-Dhabi, M. Valan Arasu, S. Ignacimuthu   +5 more
semanticscholar   +1 more source

An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction

, 2020
Naser L. Rezk, Nicole White, Angela D. M. Kashuba   +2 more
openalex   +1 more source

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study [PDF]

, 2017
Background Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL. Methods The protease and reverse transcriptase (RT) genes were systematically sequenced in samples from 756 patients with VL >50 copies/mL in ...
Assoumou, Lambert, Chaix, Marie-Laure, Costagliola, Dominique, Delaugerre, Constance, Descamps, Diane, Dos Santos, Georges, Izopet, Jacques, Marcelin, Anne-Geneviève, Masquelier, Bernard, Montes, Brigitte, Morand-Joubert, Laurence, Pakianather, Sophie, Plantier, Jean-Christophe, Ruffault, Annick, Wirden, Marc, Yerly, Sabine   +15 more
core